Andrew D. Rhim, MD
-
RoleGastroenterology
-
Specialty
-
Research Program
-
Practicing Since2010
Background
Andrew D. Rhim, MD, is a board-certified gastroenterologist who specializes in treating pancreatic disorders and malignancies. His clinical practice focuses on screening and surveillance of populations at elevated risk for pancreatic cancer, including patients with neoplastic pancreatic cysts and those with a strong family history of the disease.
Dr. Rhim is an assistant professor in the Division of Digestive Diseases in the Department of Medicine at Emory University School of Medicine. Before joining Emory, he was an assistant professor of gastroenterology and served as associate director for translational research at the Ahmed Center for Pancreatic Cancer Research at UT MD Anderson Cancer Center.
He earned his medical degree from the University of Pennsylvania School of Medicine in Philadelphia. He completed his internal medicine residency and clinical fellowship in gastroenterology at the Hospital of the University of Pennsylvania, followed by a research fellowship in cancer genetics at the Abramson Family Cancer Research Institute at the University of Pennsylvania.
Titles & Roles
-
Assistant Professor, Department of MedicineEmory University School of Medicine
Education & Training
Education
- Fellowship, Gastroenterology, 2010Hospital of the University of Pennsylvania
- Residency, Internal Medicine, 2006Hospital of the University of Pennsylvania
- Medical Education, MD, 2004University of Pennsylvania Perelman School of Medicine
Board Certifications
- Internal MedicineAmerican Board of Internal Medicine, 2011Internal MedicineAmerican Board of Internal Medicine, 2008
Research
As a physician-scientist, Dr. Rhim’s interests and expertise center on the genomics and genetics of pancreatic cancer. His research aims to understand the key molecular and cellular events that drive the transformation of precancerous lesions into cancer and to explore how intratumoral heterogeneity develops in later stages.
These studies seek not only to deepen understanding of pancreatic cancer biology but also to translate findings into clinical benefit through the identification of novel biomarkers for early diagnosis of pancreatic and other solid organ cancers, and the nomination of potential drug targets to inhibit metastasis and disease progression.
Ratings & Reviews
Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.